Smart drugs: tyrosine kinase inhibitors in cancer therapy (Q34710595)

4 August 2017

1 reference

title

Smart drugs: tyrosine kinase inhibitors in cancer therapy (English)

1 reference

4 August 2017

Laura K Shawver

1 reference

4 August 2017

Dennis Slamon

series ordinal

1 reference

4 August 2017

Axel Ullrich

series ordinal

1 reference

4 August 2017

publication date

1 March 2002

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

117-123

1 reference

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Perspectives on the development of a molecularly targeted agent

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Overview of angiogenesis: Biologic implications for antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Expression, Function and Activation of the Proto-oncogenec-kitProduct in Human Leukemia Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Angiogenesis: regulators and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Involvement of platelet-derived growth factor in disease: development of specific antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Challenges for imaging angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900039-9

7 January 2021

10.1016/S1535-6108(02)00039-9

Identifiers

DOI

1 reference

4 August 2017

1 reference